Abstract
This article examines patent portfolio construction and management of three nascent technologies: nanobiotechnology, synthetic biology, and interference RNA. The author outlines how a practitioner can use patent portfolios to help his or her client to maximize long-term gain. Finally, the article advocates changes that would remove barriers to patentability and increase patent quality.
Repository Citation
Thomas M. Mackey,
Nanobiotechnology, Synthetic Biology, and RNAI: Patent Portfolios for Maximal Near-Term Commercialization and Commons for Maximal Long-Term Medical Gain,
13 Marq. Intellectual Property L. Rev. 123
(2009).
Available at: https://scholarship.law.marquette.edu/iplr/vol13/iss1/3